BCL2 and neoplasm: For example, synthetic miR-34a mimics have shown potent anti-tumor activity in preclinical models: they inhibit epithelial–mesenchymal transition (EMT) and induce apoptosis by targeting BCL2 and MET, among other oncogenes [55].